Arecor Therapeutics Plc · LSE:AREC
Arecor Therapeutics — FY2021 Earnings Presentation
23 slides from Arecor Therapeutics's earnings presentation, Apr 25, 2022
Slide 1: Advancing today's therapies to enable healthier lives
Advancing today’s therapies to enable healthier lives Final results for the year ended 31 December 2021 25 April 2022 www.arecor.com
Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or
Slide 3: Introduction
01 Introduction Page 2 Arecor 2022 | Confidential
Slide 4: Presentation Team
Presentation Team Dr Sarah Howell Susan Lowther Chief Executive Officer Chief Financial Officer Page 3 Arecor 2022 | Confidential
Slide 5: Company summary
Company summary Driving better healthcare through the transformation of today’s therapies Arestat™ proprietary technology Clinical company developing proprietary platform pipeline of enhanced medicines Significant clinical • Enhances properties of existing • Diabetes - favourable clinical data + nea
Slide 6: Operational Highlights (including post-period events)
Operational Highlights (including post-period events) Driving better healthcare through the transformation of today’s therapies Proprietary Pipeline • US Phase I clinical trial for AT247 initiated in early 2022, following FDA clearance of IND application • Positive Phase I clinical trial for AT278 s
Slide 7: A broad portfolio of de-risked and innovative assets
A broad portfolio of de-risked and innovative assets Portfolio of de-risked in-house and partnered programmes Product Area Research Preclinical Phase 1 Phase 2 Phase 3 Est launch1 Market size AT247 Diabetes 2025 Arecor Development AT278 Diabetes 2025 ~$6.4B2 AT299 Diabetes 2028 Clinical Development
Slide 8: Expanding portfolio of partnerships with five new collaborations signed in 2021
Expanding portfolio of partnerships with five new collaborations signed in 2021 Revenue generating collaborations offering future license potential Exclusive Exclusive formulation Exclusive formulation Exclusive formulation Exclusive formulation formulation study study collaboration collaboration wi
Slide 9: Best-in-class insulins for more effective treatment of diabetes
01 Best-in-class insulins for more effective treatment of diabetes Page 8 Arecor 2021 | Confidential
Slide 10: Diabetes in crisis: There is still a need for improved insulins
Diabetes in crisis: There is still a need for improved insulins A major worldwide health issue with significant unmet needs in diabetes care 537 million adults are living with diabetes $966 billion estimated global expenditure 6.7 million deaths due to diabetes in 2021 Page 9 Arecor 2022 | Confident
Slide 11: Diabetes: Portfolio of best-in-class ultra-rapid and concentrated insulins
Diabetes: Portfolio of best-in-class ultra-rapid and concentrated insulins A major worldwide health issue with significant unmet needs in diabetes care AT247, an ultra-rapid acting insulin Arecor’s goal is to improve with potential to enable fully automated artificial pancreas for Type I diabetics t
Slide 12: AT247: Improved profile vs current gold standard treatments
AT247: Improved profile vs current gold standard treatments Superiority for onset of appearance, exposure and early insulin action during 120min after dosing compared with Fiasp® and NovoRapid® Phase I clinical study¹ successfully met all primary endpoints with best-in-class profile 1Double-blind, r
Slide 13: AT247 Potential to enable transformational fully closed loop artificial pancreas
AT247 Potential to enable transformational fully closed loop artificial pancreas Improve quality and life and outcomes for Type 1 diabetic patients CGM Measures blood AT247 best-in-class PK/PD glucose levels in demonstrated in Phase I real-time clinical study AP ‘holy grail’ for people living with T
Slide 14: AT278 500 U/mL: Creating a disruptor insulin
AT278 500 U/mL: Creating a disruptor insulin Potential to be the first concentrated ultra-rapid insulin product available to patients The Need AT278 potential to be first and only ultra-concentrated rapid acting insulin • Growing number of Type 2 diabetics requiring high daily doses of insulin (>100
Slide 15: AT278 500 U/mL: Positive results from first Phase I clinical study
AT278 500 U/mL: Positive results from first Phase I clinical study; significantly accelerated PK/PD compared to 100 U/mL NovoRapid® Potential to be the first concentrated ultra-rapid insulin product available to patients Study Design • Double-blind, randomized, two-way cross over Phase 1 clinical st
Slide 16: Showcasing potential of diabetes portfolio at upcoming ATTD annual meeting
Showcasing potential of diabetes portfolio at upcoming ATTD annual meeting AT278 AT247 Oral Presentation: AT278 (U500) - PK/PD and Poster Presentation: Adjusting insulin therapy to faster safety of rapid-acting insulin analogs leads to improved concentrated insulin aspart glucose control: An in-sili
Slide 17: Discussing the clinical need for an ultra-concentrated ultra-rapid acting insulin
Discussing the clinical need for an ultra-concentrated ultra-rapid acting insulin Upcoming KOL event - Thursday 26 May at 15:00-16:30 UK time Jay Skyler Thomas Pieber Wendy Lane Davida Kruger Professor of Medicine, Professor of Medicine, Head of Clinical endocrinologist in Nurse practitioner, Henry
Slide 18: Diabetes franchise – Key upcoming milestones
Diabetes franchise – Key upcoming milestones Develop to clinical value inflexion point prior to licensing Research Pre-Clinical Phase 1 Phase 2 Upcoming Milestone AT247 - US Phase I insulin pump clinical study expected to complete Ultra Rapid H2 2022 Acting Insulin AT278 - Full results to be present
Slide 19: Financials and newsflow
03 Financials and newsflow Page 18 Arecor 2022 | Confidential
Slide 20: 2021 Financial Highlights
2021 Financial Highlights Driving better healthcare through the transformation of today’s therapies Successful AIM IPO • Raised £20m new investment at a share price of 226p • Market cap of £62.5m at Admission 2021 P&L • Total income of £1.8m (2020: £2.1m) • Investment in R&D of £5.4m (2020: £3.9m) S
Slide 21: Key Financials
Key Financials £m Year ended Year ended 31 Dec 2021 31 Dec 2020 Formulation development revenue includes 5 new deals • Future licensing opportunities Formulation development 1.2 0.8 License and milestones - 0.9 Grant income of £0.6m • Total award of £2.8m Revenue 1.2 1.7 Loss after tax of £6.2m Othe
Slide 22: Arecor: Focused on execution and delivery
Arecor: Focused on execution and delivery Key milestones 2021 2022 • £2.8m Innovate UK grant award • AT247-103 clinical results • Successful AIM IPO raising £20m • AT278 Initiate T2D clinical study • AT278 Phase I study results • HIK AT282 achieve next license • AT247-103 US IND allowance milestone
Slide 23: Contact Q & A
Contact Sarah Howell, CEO sarah.howell@arecor.com Q&A Susan Lowther, CFO susan.lowther@arecor.com www.arecor.com